Blood Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunomodulator
Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation
October 5th, 2006
Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. According to recently published research from Germany, "Evidence from the animal model suggests that proteasome inhibitors may have immunosuppressive properties; however, their effects on the human immune system remain poorly investigated. "Here, we show that bortezomib, a proteasome inhibitor with anticancer activity, impairs several immune properties of human monocyte-derived dendritic cells (DCs). Namely, exposure of DCs to bortezomib reduces their phagocytic capacity, as shown by FITC-labeled dextran internalization and mannose-receptor CD206 downregulation." ...
Source: Blood Weekly (2006-10-05)
|
